STROBE Statement—Checklist of items that should be included in reports of *cross-sectional studies*

		Item No	Recommendation
Title and abstract		1	(a) Indicate the study's design with a commonly used term in the title or the abstract
			(b) Provide in the abstract an informative and balanced summary of what was done
			and what was found
Introduction			
Background/rationa	ıle 6	2	Explain the scientific background and rationale for the investigation being reported
Objectives	6	3	State specific objectives, including any prespecified hypotheses
Methods			
Study design	7	4	Present key elements of study design early in the paper
Setting	7	5	Describe the setting, locations, and relevant dates, including periods of recruitment,
	,		exposure, follow-up, and data collection
Participants	7	6	(a) Give the eligibility criteria, and the sources and methods of selection of
			participants
Variables	-	7 7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect
	,		modifiers. Give diagnostic criteria, if applicable
Data sources/		8*	For each variable of interest, give sources of data and details of methods of
measurement	8		assessment (measurement). Describe comparability of assessment methods if there is
			more than one group
Bias		9	Describe any efforts to address potential sources of bias
Study size	7	10	Explain how the study size was arrived at
Quantitative variable	les 7	11	Explain how quantitative variables were handled in the analyses. If applicable,
			describe which groupings were chosen and why
Statistical methods	Q	12	(a) Describe all statistical methods, including those used to control for confounding
	O		(b) Describe any methods used to examine subgroups and interactions
			(c) Explain how missing data were addressed
			(d) If applicable, describe analytical methods taking account of sampling strategy
			(e) Describe any sensitivity analyses
Results			-
Participants		13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially
			eligible, examined for eligibility, confirmed eligible, included in the study,
			completing follow-up, and analysed
	10		(b) Give reasons for non-participation at each stage
			(c) Consider use of a flow diagram
Descriptive data		14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and
Descriptive data	10		information on exposures and potential confounders
			(b) Indicate number of participants with missing data for each variable of interest
Outcome data	10-13	15*	Report numbers of outcome events or summary measures
Main results	10 10	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and
wani icsuits		10	their precision (eg, 95% confidence interval). Make clear which confounders were
			adjusted for and why they were included
		12	(b) Report category boundaries when continuous variables were categorized
			(c) If relevant, consider translating estimates of relative risk into absolute risk for a
			meaningful time period
Other analyses	10	17	Report other analyses done—eg analyses of subgroups and interactions, and
Curor anaryses	12	-/	sensitivity analyses
			behometry unuryboo

Discussion					
Key results	14	18	Summarise key results with reference to study objectives		
Limitations	16	19	Discuss limitations of the study, taking into account sources of potential bias or		
			imprecision. Discuss both direction and magnitude of any potential bias		
Interpretation	18	20	Give a cautious overall interpretation of results considering objectives, limitations,		
	1.0		multiplicity of analyses, results from similar studies, and other relevant evidence		
Generalisability	18 21		Discuss the generalisability (external validity) of the study results		
Other information					
Funding	None 22		Give the source of funding and the role of the funders for the present study and, if		
			applicable, for the original study on which the present article is based		

^{*}Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.